Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4495368 | 0.85 | ALDH1A1 (0.35) | ALDH1A1LMNASMN1; SMN2MAOBGCGR | |
| SCHEMBL4504814 | 0.78 | CETP (0.36) | ALDH1A1MAOBGCGRKDM4ETP53 | |
| SCHEMBL4503613 | 0.77 | CETP (0.34) | ALDH1A1MAOBGCGRTP53RXFP1 | |
| SCHEMBL4500724 | 0.75 | CETP (0.33) | GCGRKDM4EHTT | |
| SCHEMBL4508705 | 0.75 | MAOB (0.39) | ALDH1A1LMNASMN1; SMN2MAOBKDM4E | |
| SCHEMBL4501365 | 0.72 | MAOB (0.37) | ALDH1A1LMNASMN1; SMN2MAOBGCGR | |
| SCHEMBL4493258 | 0.71 | ALDH1A1 (0.35) | ALDH1A1LMNASMN1; SMN2MAOBKDM4E | |
| SCHEMBL4505882 | 0.70 | CETP (0.41) | ALDH1A1MAOBGCGRTP53RXFP1 | |
| SCHEMBL4505879 | 0.70 | CETP (0.41) | ALDH1A1MAOBGCGRTP53RXFP1 | |
| SCHEMBL4505876 | 0.68 | CETP (0.40) | GCGRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227511-B2 | Substituted chromanol derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-07-24 | — | — | US | disclosed |
| US-20090306197-A1 | Substituted Chromanol Derivatives and Their Use | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306197-A1 | Substituted Chromanol Derivatives and Their Use | CYP46A1, CBX3, CDYL | ALDH1A1 1180/4885LMNA 98/4885SMN1; SMN2 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.